RB1 and breast carcinoma: Multiple studies have demonstrated that the CDK–RB–E2Fs pathway is critical for the control of cell proliferation, and the CDK–RB–E2Fs pathway is a driver of multiple hallmarks of breast cancer and consequently could be a good target for therapy in this disease (24).